Impact of P-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 502-507

  Jin, Liang ^a   Li, Jian ^a   Nation, Roger L ^a   Nicolazzo, Joseph A ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; ELACRIDAR; GLYCOPROTEIN P; LIPOPOLYSACCHARIDE; SODIUM CHLORIDE; VALSPODAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG TRANSPORT; DRUG UPTAKE; MALE; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL;

ACRIDINES; ANIMALS; ANIMALS, OUTBRED STRAINS; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; COLISTIN; CYCLOSPORINS; LIPOPOLYSACCHARIDES; MALE; MICE; P-GLYCOPROTEIN; TETRAHYDROISOQUINOLINES;

EID: 78751695932     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01273-10     Document Type: Article

References (32)

1. Antachopoulos, C., et al. 2010. Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob. Agents Chemother. 54:3985-3987.
2. Bailer, A. J. 1988. Testing for the equality of area under the curves when using destructive measurement techniques. J. Pharmacokinet. Biopharm. 16:303-309.
3. Banks, W. A., et al. 2008. Nitric oxide isoenzymes regulate lipopolysaccharide-enhanced insulin transport across the blood-brain barrier. Endocrinology 149:1514-1523.
4. Banks, W. A., M. Goulet, J. R. Rusche, M. L. Niehoff, and R. Boismenu. 2002. Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse. J. Pharmacol. Exp. Ther. 302:1062-1069.
5. Bergen, P. J., J. Li, C. R. Rayner, and R. L. Nation. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1953-1958.
6. Bosso, J. A., C. A. Liptak, D. K. Seilheimer, and G. M. Harrison. 1991. Toxicity of colistin in cystic fibrosis patients. DICP 25:1168-1170.
7. Didziapetris, R., P. Japertas, A. Avdeef, and A. Petrauskas. 2003. Classification analysis of P-glycoprotein substrate specificity. J. Drug Target. 11:391-406. (Pubitemid 38455825)
8. Evans, M. E., D. J. Feola, and R. P. Rapp. 1999. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 33:960-967.
9. Falagas, M. E., and S. K. Kasiakou. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341.
10. Falagas, M. E., and S. K. Kasiakou. 2006. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care 10:R27.
11. Hartz, A. M., B. Bauer, G. Fricker, and D. S. Miller. 2006. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol. Pharmacol. 69:462-470.
12. Hermsen, E. D., C. J. Sullivan, and J. C. Rotschafer. 2003. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect. Dis. Clin. North Am. 17:545-562.
13. Hitchcock, S. A. 2008. Blood-brain barrier permeability considerations for CNS-targeted compound library design. Curr. Opin. Chem. Biol. 12:318-323.
14. Huber, J. D., R. D. Egleton, and T. P. Davis. 2001. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 24:719-725.
15. Jiménez-Mejías, M. E., et al. 2002. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 21:212-214.
16. Jin, L., J. Li, R. L. Nation, and J. A. Nicolazzo. 2009. Brain penetration of colistin in mice assessed by a novel high-performance liquid chromatographic technique. Antimicrob. Agents Chemother. 53:4247-4251.
17. Landman, D., C. Georgescu, D. A. Martin, and J. Quale. 2008. Polymyxins revisited. Clin. Microbiol. Rev. 21:449-465.
18. Lee, S. Y., et al. 2008. Multidrug-resistant Acinetobacter meningitis in a 3-year-old boy treated with i.v. colistin. Pediatr. Int. 50:584-585.
19. Li, J., R. L. Nation, R. W. Milne, J. D. Turnidge, and K. Coulthard. 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25:11-25.
20. Li, J., et al. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
21. Markantonis, S. L., et al. 2009. Penetration of colistin into cerebrospinal fluid. Antimicrob. Agents Chemother. 53:4907-4910.
22. Minami, T., J. Okazaki, A. Kawabata, R. Kuroda, and Y. Okazaki. 1998. Penetration of cisplatin into mouse brain by lipopolysaccharide. Toxicology 130:107-113.
23. Nonaka, N., S. Shioda, and W. A. Banks. 2005. Effect of lipopolysaccharide on the transport of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier. Exp. Neurol. 191:137-144.
24. Payne, D. J., M. N. Gwynn, D. J. Holmes, and D. L. Pompliano. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40.
25. Post, L. O., D. E. Farrell, C. V. Cope, J. D. Baker, and M. J. Myers. 2003. The effect of endotoxin and dexamethasone on enrofloxacin pharmacokinetic parameters in swine. J. Pharmacol. Exp. Ther. 304:889-895.
26. Quagliarello, V., and W. M. Scheld. 1992. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N. Engl. J. Med. 327:864-872.
27. Schinkel, A. H. 1999. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 36:179-194.
28. Schinkel, A. H., E. Wagenaar, L. van Deemter, C. A. Mol, and P. Borst. 1995. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1698-1705.
29. Shen, S., and W. Zhang. 2010. ABC transporters and drug efflux at the blood-brain barrier. Rev. Neurosci. 21:29-53.
30. Takasato, Y., S. I. Rapoport, and Q. R. Smith. 1984. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247:H484-H493.
31. Uchiumi, D., M. Kobayashi, T. Tachikawa, and K. Hasegawa. 2004. Subcutaneous and continuous administration of lipopolysaccharide increases serum levels of triglyceride and monocyte chemoattractant protein-1 in rats. J. Periodontal Res. 39:120-128.
32. Wispelwey, B., A. J. Lesse, E. J. Hansen, and W. M. Scheld. 1988. Haemophilus influenzae lipopolysaccharide-induced blood brain barrier permeability during experimental meningitis in the rat. J. Clin. Invest. 82:1339-1346.